Loading...
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Cuzick, Jack Baum, Michael Buzdar, Aman Dowsett, Mitch Forbes, John F Hoctin-Boes, G Houghton, Joan Locker, Gershon Tobias, J S
Cuzick, Jack
Baum, Michael
Buzdar, Aman
Dowsett, Mitch
Forbes, John F
Hoctin-Boes, G
Houghton, Joan
Locker, Gershon
Tobias, J S
Citations
Altmetric:
Abstract
The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) and time-to-recurrence (402 vs 498, 0.79, 0.70-0.90, p=0.0005), and significantly reduced distant metastases (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 12-62, p=0.01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.
Description
Date
2005-01
Publisher
Collections
Keywords
Breast Cancer
Oestrogen Antagonists
Cancer Metastasis
Cancer Recurrence
Oestrogen Antagonists
Cancer Metastasis
Cancer Recurrence
Type
Article
Citation
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer., 365 (9453):60-2 Lancet